MARKET

ALDX

ALDX

Aldeyra Therapeu
NASDAQ
3.870
-0.200
-4.91%
Closed 17:28 07/18 EDT
OPEN
4.040
PREV CLOSE
4.070
HIGH
4.200
LOW
3.850
VOLUME
223.96K
TURNOVER
0
52 WEEK HIGH
8.38
52 WEEK LOW
1.420
MARKET CAP
229.93M
P/E (TTM)
-7.6181
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ALDX last week (0708-0712)?
Weekly Report · 4d ago
Weekly Report: what happened at ALDX last week (0701-0705)?
Weekly Report · 07/08 09:42
Weekly Report: what happened at ALDX last week (0624-0628)?
Weekly Report · 07/01 09:42
Weekly Report: what happened at ALDX last week (0617-0621)?
Weekly Report · 06/24 09:45
Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable
Aldeyra Therapeutics, Inc. Announced advancement of new RASP modulators and recent preclinical data in obesity in conjunction with an Investor Roundtable scheduled for June 20, 2024. The company is a biotechnology company devoted to discovering and developing innovative therapies to treat immune-mediated and metabolic diseases.
Barchart · 06/20 06:00
Analysts Have Conflicting Sentiments on These Healthcare Companies: Aldeyra Therapeutics (ALDX), Cardinal Health (CAH) and Roche Holding AG (OtherRHHVF)
TipRanks · 06/17 10:10
Weekly Report: what happened at ALDX last week (0610-0614)?
Weekly Report · 06/17 09:42
Aldeyra Therapeutics Completes Phase 3 Trial Enrollment for Reproxalap
TipRanks · 06/13 11:50
More
About ALDX
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.

Webull offers Aldeyra Therapeutics Inc stock information, including NASDAQ: ALDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALDX stock methods without spending real money on the virtual paper trading platform.